Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
作者信息
LaCasce Ann S, Bociek R Gregory, Sawas Ahmed, Caimi Paolo, Agura Edward, Matous Jeffrey, Ansell Stephen M, Crosswell Howland E, Islas-Ohlmayer Miguel, Behler Caroline, Cheung Eric, Forero-Torres Andres, Vose Julie, O'Connor Owen A, Josephson Neil, Wang Yinghui, Advani Ranjana
机构信息
Dana-Farber Cancer Institute, Boston, MA, USA.
University of Nebraska Medical Center, Omaha, NE, USA.
出版信息
Br J Haematol. 2020 May;189(3):e86-e90. doi: 10.1111/bjh.16499. Epub 2020 Feb 12.
PMID:32048731
Abstract
摘要
Zotero 插件